ГоловнаArchive of numbers2022Volume 30, issue 2(111)Evaluation of therapy targets in recurrent depressive disorders
Title of the article Evaluation of therapy targets in recurrent depressive disorders
Authors Maruta Natalia
Panko Tamara
Semikina Olena
Zavalko Yurii
In the section DIAGNOSTICS AND THERAPY OF MENTAL AND NARCOLOGICAL DISORDERS
Year 2022 Issue Volume 30, issue 2(111) Pages 54-60
Type of article Scientific article Index UDK 616.8-008.64-08 Index BBK -
Abstract DOI: https://doi.org/10.36927/2079-0325-V30-is2-2022-9

 According to the WHO, more than 350 million people suffer from depres- sive disorders. The etiology and pathogen- esis of depressive episodes and recurrent depressive disorders have not yet been definitively established. The formation of depressive disorders is due to a com- bination of such factors as biological (constitutional and genetic), psychological and social. Taking into account the level of prevalence of depressive disorders, the assessment of their clinical and psy- chopathological features and approaches to their therapy continues. In order to de- termine the targets of thera py for recur- rent depressive disorders, an examination of patients with recurrent depressive dis- orders was conducted. In the conditions of the Department of borderline psychiatry of the "Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine" SI: 175 patients with recurrent depression were examined, among them 74.85 % were women and 25.15 % were men. The ave- rage age of the examinees was 46.79 years (women — 52.25, men — 41.32). Based on the assessment of clinical and psychological manifestations of recurrent depressive disorders and psychopatho- logical aspects, the targets of therapeutic influence are established: the severity of a depressive episode (mild, moderate, severe), the specificity of psychotraumatic experiences, parameters of anti-vitality and vitality, structural features of adaptation potential.
Key words recurrent depressive disorder, clinical and psychopathological features, targets of therapy
Access to full text version of the article pdf download
Bibliography 1. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx). http://ghdx.healthdata.org/ gbd-results-tool?params=gbd-api-2019-permalink/d780dff- be8a381b25e1416884959e88b.
2. Vos T., Flaxman A. D., Naghavi M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and inju- ries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013, 380 (9859): 2163–2196
3. World Health Organization. (2017). Depression and other common mental disorders: global health estimates. https://apps. who.int/iris/handle/10665/254610. License: CC BY-NC-SA 3.0 IGO.
4. World Health Organization. (2008). The global burden of disease : 2004 update. World Health Organization. https:// apps.who.int/iris/handle/10665/43942.
5. Mosolov S. N., Vertogradova O. P., Panteleeva G. P. i dr. Profilakticheskaya e'ffektivnost' tianeptina pri rekurrentnoj de- pressii s chasty'mi obostreniyami. Zhurnal nevrologii i psixiatrii im. S. S. Korsakova. 2004; 104 (9): 32–8.
6. Kessler R.C., Angermeyer M., Anthony J.C. et al. Lifetime Prevalence and Age-Of-Onset Distributions of Mental Disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry. 2007; 6 (3): 168–76. PMID: 18188442.
7. Shelton R. C., Tollefson G. D., Tohen M., Stahl S., Gan- non K. S., Jacobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spen- cer K. A., Feldman P. D., Meltzer H. Y. A novel augmentation strategy for treating resistant major depression. Am J Psychiat. 2001; 158(1):131–34. doi: 10.1176/appi.ajp.158.1.131.
8. Altamura A. C., Percudani M. The use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. J Clin Psychiat. 1993; 54 (8): 29–37. PMID: 8253703.
9. Kessing L.V., Xansen M.G., Andersen P.K., Angst Dzh. Chislo e'pizodov kak prognosti ches kij faktor riska razviti- ya recidiva pri depressivnom i bipolyarnom rasstrojstvax: pozhiznenny'j prognoz (rasshirenny'j referat). Psixiatriya i psixo- farmakoterapiya. 2008; 5.
10. Qaseem A., Snow V., Denberg T. D. et al. Using Second- Generation Antidepressants to Treat Depressive Disorders: A Clinical Practice Guideline from American College of Physi- cians. Ann Int Med. 2008; 149 (18): 725–33.
11. Fava C. A., Ruini C., Belaise C. The concept of recovery in major depression. Psychol Med. 2007; 48:103–11.
 12. Menza M., Marin H., Opper R.S. Residual symptoms in depression: Can treatment be symptom specific? J Clin Psychiatry. 2003; 64:516–23.
13. Evans-Lacko S., Aguilar-Gaxiola S., Al-Hamzawi A., et al. Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys. Psychol Med. 2018; 48(9): 1560–1571.
14. Serretti A., Cavallini M. C., Macciardi F. et al. Social adjustment and self-esteem in remitted with mood disorders. Eur Psychiatry. 1999; 14:137–42.